39 ASCT1 and ASCT2, which have mainly been studied in the context of glutamine dependence, are expressed at high levels in different cancer types, 40,41,42 prompting these transporters to be considered putative therapeutic targets in cancer, with different inhibitors currently under investigation
Do not stop or change a GLP-1 medication on your own
Because response and tolerability vary, clinician-guided dosing and patient education are essential to ensure appropriate use, manage potential side effects, and establish realistic expectations for treatment outcomes
An increased risk of amputations was reported in the CANVAS Program trial but has not been demonstrated in any other clinical trial nor was there any signal of this issue in a meta-analysis involving 57,713 participants [54]
The weight loss advantage of retatrutide over tirzepatide appears to be approximately 6 percentage points at the highest doses, a clinically meaningful difference